Endocyte, Merck Ink Cancer Treatment Deal

Source: Inside Indiana Business

Indiana Company Could Net $1B

West Lafayette-based Endocyte Inc. (Nasdaq: ECYT) and Merck and Co. (NYSE:MRK) have formed a partnership to develop and commercialize a cancer therapy drug. The deal could be worth $1 billion to Endocyte, and Chief Executive Officer Ron Ellis says the treatment has yielded promising results in ovarian and lung cancer patients. He says the agreement with Merck will allow the drug to be tested more quickly and marketed globally. Read More Ellis says the partnership positions the company for faster growth.



Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: